Close button
Enquiry IconContact Us
Logo

Ulcerative colitis is a category of an inflammatory bowel disease that results in inflammation and sores in the digestive tract. Ulcerative colitis makes effect on the inner lining of the large intestine (colon) and rectum. Usually, symptoms can be seen gradually depending upon the severity of inflammation. Mild symptoms can be cured by drug therapy but surgical treatment is needed in case of severity. Ulcerative colitis may lead to colon cancer if persists for over 8 years or longer. Increasing healthcare preventative measures also progressively becoming more and more sensitive to seek the advantages of the therapy. In preventative healthcare, drugs and novel therapies also reduce the chance of getting colon cancer. Possible complications associated with ulcerative colitis include perforated colon, a rapidly swelling colon, severe bleeding, and osteoporosis, increased risk of blood clots in veins and arteries, and severe dehydration. The exact cause for ulcerative colitis is not known, but the possible reasons can be genetic factors, environmental changes, or malfunctioning of immune system. The ulcerative colitis can be prevented by simple healthy habits such as eating small meals throughout the day, staying well hydrated throughout the day, avoiding fatty foods, and limiting intake of high-fiber food.

The China ulcerative colitis market is estimated to be valued at US$ 185 million in 2021 and is expected to exhibit a CAGR of 2.9% over the forecast period (2021-2028).

The increasing drug product pipeline is expected to drive growth of the China ulcerative colitis market over the forecast period.

For instance, according to the updates published on the U.S. National Library of Medicine, in June 2020, Mirikizumab, a biologic product is being studied in the phase-II of clinical trials for the ulcerative colitis treatment. Mirikizumab blocks the cytokine interleukin 23 activity. Intrerleukin-23 plays a significant role in a signalling pathway which triggers inflammation.

Figure 1. China Ulcerative Colitis Market Value (US$ Mn.), By Drug Therapy, 2021

China Ulcerative Colitis  | Coherent Market Insights

The increase in ongoing clinical trials and research and development activities for the treatment of ulcerative colitis disease is expected to drive the market growth over the forecast period.

For instance, in September 2019, Pfizer registered a phase II b trial for the efficacy and safety assessment of PF-06480605 in adults with moderate to severe ulcerative colitis. PF-06480605 is an antibody which blocks tumor necrosis factor (TNF).

CMI table icon

China Ulcerative Colitis Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 185 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 2.9% 2028 Value Projection: US$ 227 Mn
Geographies covered:
  • China
Segments covered:
  • By Drug Therapy: 5-Aminosalicylates, Monoclonal Antibodies, Steroids, Immunomodulators, Antibiotics.
  • By Route of Administration: Oral, Parenteral
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

AbbVie Inc., Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company,  AstraZeneca, Pfizer Inc., Amgen, BRISTOL-MYERS SQUIBB,  Finch Therapeutics Group, Inc.,  Athos Therapeutics, Inc.,  Teva Pharmaceutical Industries Ltd., and Tillotts Pharma AG

Growth Drivers:
  • Growing prevalence of ulcerative colitis
  • Increase in lifestyle related risk factors
  • Emergence of biosimilars
  • Increasing drug approvals and launches
Restraints & Challenges:
  • Strict regulatory standards
  • Risk of adverse reactions associated with ulcerative colitis drugs
  • Lack of awareness regarding the ulcerative colitis condition
Opportunity:
  • To develop generic drugs for the treatment of ulcerative colitis

Figure 2. China Ulcerative Colitis Market Value (US$ Mn.), By Route of Administration, 2021

China Ulcerative Colitis  | Coherent Market Insights

The increasing product launches and approvals are expected to drive the market growth over the forecast period.

For instance, in December 2019, Amgen Inc. announced that the U.S. Food and Drug Administration (FDA) had approved AVSOLA, for the treatment of ulcerative colitis in the adult and pediatric population.

China Ulcerative Colitis Market – Impact of Coronavirus (COVID-19) Pandemic

The healthcare sector is at the epicentre global unprecedented pandemic challenge. The government has offered all the needed support to private sector, whether it is testing support, preparing isolation beds for COVID-19 positive patient's treatment, or deploying staff and equipment in hospitals. While the private healthcare industry is fully prepared for every eventuality, the sector is also facing a twin-burden: first, investing additional workforce, equipment, consumables, and other resources to ensure 100% preparation for safety in the hospitals and, if required, consequent treatment of patients. Secondly, the healthcare industry is experiencing a sharp drop in outpatient footfalls, optional surgeries, and international patients. The industry has been witnessing a business loss. This trend of Covid-19 impact is expected to continue for at least more 3-6 months from November 2021. The sector's costs is predominantly around 80% fixed; it is likely that there will be losses and a severe impact on cash flows during forecast period.

Due to China's current crisis, pharmaceutical sector finds it challenging to source raw materials and components from the Chinese market. Though some factories in China have restored operations, some critical parts and the raw material shortage still exist. Thus, adversely affecting various companies' margins and profitability, which are importing small components and other essentials to develop finished products. This factor can also create upward pressure on the prices of drug in the short term. However, from another perspective, the COVID-19 outbreak has eventually provided a unique opportunity to explore business. There is a possibility of focus shifting from China to India as the primary producer and supplier of APIs, IVDs, and generic drugs.

China Ulcerative Colitis Market - Restraint

The risk of adverse reactions od ulcerative colitis drugs, strict regulatory standards, and lack of awareness regarding ulcerative colitis condition are the factors expected to hinder growth of the China ulcerative colitis market over the forecast period.

Due to the strict government biosimilar authorization standards and the increasing patent expiry of the old drugs are the key constraints behind the development of ulcerative colitis over the forecast period. In addition, the increasing trend in generic prescription drugs is estimated to hinder market growth.

Negative effects of a drug used to treat ulcerative colitis may have an impact on the human health and are expected to prevent market growth during a forecast period. Common side effects involve diabetes rounding, high pressure on the blood body, cataracts, weight gain, face (moon face), acne, increased hair on the body, and increased susceptibility to infections, glaucoma, muscle weakness, depression, irritability, insomnia and bone dilution. The most serious complication with long-term drug use is aseptic hip joint necrosis.

Colitis ulcerative (UC) is a lifelong disease that progresses over time. Lack of awareness of the public can contribute to late diagnosis, late discussion with primary care doctors and the development of potentially preventable disease complications. Limited understanding of ulcerative colitis among people can hamper market growth over the projected period.

Key Players

  • Major players operating in the China ulcerative colitis market include AbbVie Inc., Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company,  AstraZeneca, Pfizer Inc., Amgen, BRISTOL-MYERS SQUIBB,  Athos Therapeutics, Inc., Finch Therapeutics Group, Inc., Tillotts Pharma AG, and Teva Pharmaceutical Industries Ltd.

Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. This disease can affect people of any age. The major symptoms of this disease include diarrhea, belly pain/cramps, bleeding from the rectum, also other indications include sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan, and blood test. If ulcerative colitis persists for over eight years or longer, it may lead to colon cancer.

The people having mild symptoms of this disease can be cured by over the counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps to prevent colon cancer. The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system.

Market Dynamics

The growing prevalence of ulcerative colitis, increase in lifestyle related risk factors, emergence of biosimilars, ongoing clinical trials, rise in drug approvals and launches, increasing R&D expenditure and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the China ulcerative colitis market over the forecast period.

For instance, in May 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for XELJANZ (tofacitinib) to treat adult patients with moderate to severe active ulcerative colitis.

Key features of the study:

  • This report provides in-depth analysis of the China ulcerative colitis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the China ulcerative colitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AbbVie Inc., Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company,  AstraZeneca, Pfizer Inc., Amgen, BRISTOL-MYERS SQUIBB,  Athos Therapeutics, Inc., Finch Therapeutics Group, Inc., Tillotts Pharma AG, and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The China ulcerative colitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the China ulcerative colitis market

Detailed Segmentation:

  • China Ulcerative Colitis Market, By Drug Therapy:
    • 5-Aminosalicylates
    • Monoclonal Antibodies
    • Steroids
    • Immunomodulators
    • Antibiotics
  • China Ulcerative Colitis Market, By Route of Administration:
    • Oral
    • Parenteral
  • China Ulcerative Colitis Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • AbbVie Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Celltrion Healthcare
    • Johnson & Johnson Services, Inc.
    • F. Hoffmann-La Roche AG
    • Arena Pharmaceuticals
    • Takeda Pharmaceuticals Company Ltd.
    • GlaxoSmithKline Plc.
    • Eli Lilly and Company
    • AstraZeneca
    • Pfizer Inc.
    • Amgen
    • BRISTOL-MYERS SQUIBB
    • Athos Therapeutics, Inc.
    • Finch Therapeutics Group, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Tillotts Pharma AG

 “*” marked represents similar segmentation in other categories in the respective section.

FAQ

Frequently Asked Questions

The China ulcerative colitis market size is estimated to be valued at US$ 185 million in 2021 and is expected to exhibit a CAGR of 2.9% between 2021 and 2028.

The growing prevalence of ulcerative colitis, increase in lifestyle related risk factors, emergence of biosimilars, ongoing clinical trials, rise in drug approvals and launches, increasing R&D expenditure are expected to drive the market growth over the forecast period.

5-Aminosalicylates segment is expected to hold major market share, owing to increasing drug approvals and launches during the forecast period.

Major factors hampering growth of the market include strict regulatory standards, side effects of ulcerative colitis drugs, and lack of awareness regarding ulcerative colitis condition.

Major players operating in the market include AbbVie Inc., Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company,  AstraZeneca, Pfizer Inc., Amgen, BRISTOL-MYERS SQUIBB,  Athos Therapeutics, Inc., Finch Therapeutics Group, Inc., Tillotts Pharma AG, and Teva Pharmaceutical Industries Ltd.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.